Harald Reinhart

Harald Reinhart, M.D., has been our Chief Medical Officer, Autoimmune & Infectious Disease since 2017. He is currently Adjunct Clinical Professor of infectious diseases at Yale School of Medicine. Prior to joining Zai Lab, Dr. Reinhart worked at Shionogi US as Head of Clinical Development and Medical Affairs, directing a broad portfolio of antibiotics, diabetes, allergy and pain medications. He guided several compounds through regulatory meetings, and obtained approval for ospemifene. Between 2003 and 2011, he held senior roles at Novartis where he oversaw successful filings of SNDAs and NDAs for Coartem, Famvir, Sebivo, and Cubicin, managed clinical development groups for infectious disease, immunity, transplantation, and renal disease. He supervised the transitioning of research projects into clinical developmenmt. In the years before, he was International Clinical Project Manager in charge of ciprofloxacin and acarbose at Bayer Corp., with several successful SNDAs and approvals.

Dr. Reinhart holds a medical degree from the University of Würzburg in Germany where he trained in anesthesiology. He completed his medical specialty training in the United States with board-certifications in internal medicine and infectious diseases.